PA-BLACK-BOX
3.11.2021 13:02:10 CET | Business Wire | Press release
Black Box, a leading global solutions integrator, announced today that it has joined with industry wireless communications innovator Nokia to provide the most complete, next-generation OnGo® private wireless/CBRS network for Industry 4.0. The partnership allows Black Box to drive innovation in connectivity and the adoption of private networks, giving the industrial manufacturing market superior options for wireless networking. Black Box explains that OnGo® — an even-licensed, low-band wireless spectrum that gives manufacturers access to private wireless connectivity at a fraction of the cost associated with LTE — mirrors the simplicity of Wi-Fi while providing secure, cost-effective LTE coverage for enterprise wireless traffic and IoT applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005142/en/
“Nokia welcomes Black Box to our Global Partner Program to help meet growing demand for private 4G/5G campus networks,” said Vikas Trehan, vice president, channels and alliances for Nokia. “Black Box’s intimate knowledge and trusted relationships within these enterprise campus networks, combined with world-class products and services from Nokia, will help realize the Industry 4.0 vision.”
“Private wireless and emerging private 5G networks are poised to redefine the corporate wireless networking space. Large campuses and sites like airports and large logistics and distribution hubs are pushing current WLAN standards to their technological limits,” said Bill Holman, vice president and general manager of 5G technologies at Black Box. “Thanks to our partnership with Nokia, sites like those can now break free from the limitations of WLAN and get exactly the wireless connectivity they need.”
Black Box designs, builds, and manages a full range of wireless technologies to support connected enterprise, delivering digital workplace connectivity across multiple industries. Leading manufacturers turn to Black Box to help incorporate OnGo® and 5G into their existing and future wireless networks. With Nokia Digital Automation Cloud (DAC) end-to-end private wireless, Black Box helps clients realize the full potential of Industry 4.0.
Further information about Black Box and the company’s global solutions integration services offerings is available at www.blackbox.com .
About Nokia
As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks with intellectual property and long-term research led by the award-winning Nokia Bell Labs. Nokia Digital Automation Cloud is a high-performance, LTE/5G end-to-end private wireless networking and edge computing platform. Delivering secure, plug and play, reliable wireless connectivity, Nokia DAC enables industrial use-cases leveraging real-time data for smart manufacturing, predictive maintenance, remote operations and Industrial Internet of Things (IoT) opportunities.
About Black Box
Black Box® is a trusted IT solutions provider delivering cutting-edge technology solutions and world-class consulting services to businesses on every continent. The breadth of our global reach and depth of expertise accelerate customer success by bringing people, ideas, and technology together to solve real-world business problems. Our IT infrastructure solutions, services, and products enable secure, flawless connectivity and meaningful collaboration across town or around the globe.
Black Box is a wholly owned subsidiary of AGC Networks. To learn more, visit the Black Box website at www.blackbox.com . Follow the company on Twitter @BlackBox_ns. Black Box® and the Double Diamond logo are registered trademarks of BB Technologies Inc.
All other trademarks referenced herein are the property of their respective owners.
PR Link: www.wallstcom.com/BlackBox/211103-Black_Box-Nokia_Partnership.docx
Photo: www.wallstcom.com/BlackBox/BlackBox-Nokia_OnGo-Private_Wireless_Network.jpg
Black Box and Nokia Team Up to Create OnGo® Private Wireless/CBRS Network for Industry 4.0
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005142/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom